Randomised, controlled trials of blockade of IL-1β have been performed to investigate any improvement of β-cell function in recent-onset T1D using canakinumab, a human monoclonal anti-IL-1β antibody (18). This evidence concerns the gene IL1B and type 1 diabetes mellitus.